Additionally, investigational drugs targeting C5 such as Crovalimab (NCT04861259) and gefurulimab (NCT06208488) (C5 inhibitors), Cemdisiran (a siRNA targeting the C5 mRNA transcript- NCT03841448, NCT03999840) are in various stages of clinical trials in several glomerular diseases, including an atypical HUS, IgA nephropathy, lupus nephritis, membranous nephropathy and focal segmental glomerulosclerosis (NCT05314231). Here, C5 is linked to lupus nephritis.